BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
State asks High Court to reject challenge to anti-UNRWA laws ahead of Monday hearing- Ukraine demands army of 800,000 under peace plan
- Arctic is again the hottest it's been in 125 years, with record-low sea ice, NOAA report says
- RFK Jr. succeeds in changing hepatitis B recommendation | The Excerpt
- The Minimized Passage Horse: Reconsidering a Symbol for the Cutting edge Period
- German economic institutes cut forecast in half over Iran war
- College students are now slightly less likely to experience severe depression, research shows – but the mental health crisis is far from over
- Cygnus XL brings cargo to the ISS for 1st time | Space photo of the day for Dec. 1, 2025
- The Craft of Do-It-Yourself Home Stylistic layout: Change Your Space
